We are a clinical-stage biotechnology company founded in 2014 focused on developing and commercializing products for the treatment of various skin disease and multiple aesthetic skin conditions. Our current product pipeline is comprised of topical treatment product candidates derived from our Spongilla platform technology which we believe have the potential to address the multiple facets of acne vulgaris, acne rosacea, psoriasis vulgaris and multiple aesthetic areas.
Our lead product candidate, DMT310, is currently in development for the once-weekly treatment of moderate-to-severe acne. It is our first product candidate being developed from our Spongilla platform to treat the multiple facets of acne by utilizing our technology’s unique mechanical and chemical components. We recently completed a successful Phase 2b trial of DMT310 for the treatment of moderate to severe acne where we achieved statistically significant results for all end points as early as week 4 and continuing until the end of study at week 12. In addition to the DMT310 program we also have a secondary product, DMT410, which utilizes our Spongilla technology to aid in the topical delivery of large molecules, such as botulinum toxin for the treatment of various skin diseases and aesthetic conditions. We are currently completing a Phase 1, proof of concept study of DMT410 for the treatment of various aesthetic conditions.